Fairmount Funds Management LLC Nuvalent, Inc. Transaction History
Fairmount Funds Management LLC
- $615 Million
- Q3 2024
A detailed history of Fairmount Funds Management LLC transactions in Nuvalent, Inc. stock. As of the latest transaction made, Fairmount Funds Management LLC holds 1,687,064 shares of NUVL stock, worth $147 Million. This represents 28.04% of its overall portfolio holdings.
Number of Shares
1,687,064
Previous 1,924,626
12.34%
Holding current value
$147 Million
Previous $146 Million
18.21%
% of portfolio
28.04%
Previous 28.98%
Shares
9 transactions
Others Institutions Holding NUVL
# of Institutions
210Shares Held
59.5MCall Options Held
450KPut Options Held
619K-
Deerfield Management Company, L.P. (Series C) New York, NY20MShares$1.75 Billion38.02% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5MShares$437 Million18.43% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.13MShares$361 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$264 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY2.98MShares$260 Million7.96% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $3.76B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...